| NCT ID | NCT04087629 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Columbia University |
| Condition | CTCL |
| Study Type | INTERVENTIONAL |
| Enrollment | 70 participants |
| Start Date | 2021-07-07 |
| Primary Completion | 2026-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 70 participants in total. It began in 2021-07-07 with a primary completion date of 2026-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose is to determine if StrataCTX® can be used as a steroid sparing agent for the treatment of cutaneous reactions related to, cutaneous T Cell lymphoma (CTCL) and chemotherapy/immunotherapy treatments than the current standard treatment - topical steroids - in people who are receiving treatment for CTCL, or chemotherapy/immunotherapy for solid/hematologic malignancies. Subjects will have CTCL and are being treated with topical steroids, or being treated with chemotherapy/immunotherapy for another condition and have had cutaneous reactions that have warranted initiation of topical steroids.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years * Ability to sign informed consent document * Patient with a diagnosis of CTCL who have contact dermatitis to topical mechlorethamine gel * Patients with a diagnosis of CTCL who have intractable pruritis * Patients with a diagnosis of CTCL who rely heavily on topical steroids for symptomatic relief * Patients on chemo/immunotherapy with drug induced rash Exclusion Criteria: * Patients currently undergoing radiotherapy * Patients currently receiving oral steroids * Patients who are unable to apply topical medications
Contact & Investigator
Larisa J. Geskin, MD
PRINCIPAL INVESTIGATOR
Columbia University
Frequently Asked Questions
Who can join the NCT04087629 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying CTCL. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04087629 currently recruiting?
Yes, NCT04087629 is actively recruiting participants. Contact the research team at ljg2145@cumc.columbia.edu for enrollment information.
Where is the NCT04087629 trial being conducted?
This trial is being conducted at New York, United States.
Who is sponsoring the NCT04087629 clinical trial?
NCT04087629 is sponsored by Columbia University. The principal investigator is Larisa J. Geskin, MD at Columbia University. The trial plans to enroll 70 participants.